FLT3
FMS-like receptor tyrosine kinase-3 (FLT3) is a member of the class III RTK (receptor tyrosine kinase) family and is expressed primarily in hematopoietic progenitor cells. Its expression in these cells means that FLT3 has an important role in the pathogenesis of AML.
FLT3 Inhibitors |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 5013 | AC 710 |
| Potent FLT3 inhibitor; also inhibits other PDGFR family members | |
| 6905 | Ceritinib |
| Potent FLT3 inhibitor; also potently inhibits ALK, IR, IGF1R and STK22D | |
| 7891 | Gilteritinib |
| Potent FLT3 inhibitor; also potently inhibits AXL | |
| 5260 | KG 5 |
| PDGFRβ, B-Raf, c-Raf, FLT3 and KIT inhibitor; antiangiogenic | |
| 3395 | Lestaurtinib |
| FLT3, JAK2 and TrkA inhibitor; also inhibits AurA and AurB | |
| 6788 | Quizartinib |
| Highly potent FLT3 inhibitor | |
| 6814 | Sorafenib |
| Flt-3 inhibitor; also inhibits Raf-1, VEGFR-2, VEGFR-3, PDGFR-β and cKIT | |
| 3037 | SU 5416 |
| Inhbitor of VEGFR, KIT, RET, MET and FLT3 | |
| 2591 | TCS 359 |
| Potent FLT3 inhibitor | |
| 5422 | XL 184 |
| Potent FLT3 inhibitor; also inhibits other RTKs | |
FMS-like receptor tyrosine kinase-3 (FLT3) is a member of the class III RTK (receptor tyrosine kinase) family and is expressed primarily in hematopoietic progenitor cells. The expression within these cells demonstrates that FLT3 has an important role in the pathogenesis of AML (acute myelogenous leukemia), under which conditions wild type receptors are overexpressed or mutated forms of the receptor are present. Inhibitors of both mutated and wild type receptors are therefore of interest in a therapeutic context.